As we approach the end of British Heart Week, we reflect on some of the key stats around heart conditions in the UK and our contribution as a company to help bring cutting-edge treatments to patients with cardiovascular diseases
British Heart Week 2022
More Insights
HTA quarterly update
Written by Ben Clark, Paloma Charlesworth, and Kiera Lander This quarterly update highlights recent and upcoming developments shaping the health technology assessment (HTA) environment across Europe, with a particular focus on rare ... Read more
Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations
Written by Jo Wallis, Head of Commercialisation and Pricing Strategy The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the ... Read more
The role of orphan drug designations in driving research and innovation for rare diseases
Written by Emma Bartram, Associate Systematic Review Analyst A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). ... Read more
HTA monthly update
By Toby Hobbs Changes to NICE ICER thresholds confirmed NICE has announced that from April 2026 there will be an increase to its cost-effectiveness threshold. This marks one of the biggest shifts in UK Health technology assessment ... Read more